Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $179.9 million.

  • Tg Therapeutics' Cash & Equivalents fell 8.95% to $178.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.3 million, marking a year-over-year decrease of 8.95%. This contributed to the annual value of $179.9 million for FY2024, which is 93.57% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Cash & Equivalents is $179.9 million, which was up 93.57% from $92.9 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Cash & Equivalents registered a high of $553.4 million during FY2020, and its lowest value of $92.9 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $125.0 million, with a median of $102.3 million in 2022.
  • In the last 5 years, Tg Therapeutics' Cash & Equivalents spiked by 391.35% in 2020 and then slumped by 65.77% in 2022.
  • Yearly analysis of 5 years shows Tg Therapeutics' Cash & Equivalents stood at $553.4 million in 2020, then crashed by 45.99% to $298.9 million in 2021, then tumbled by 65.77% to $102.3 million in 2022, then decreased by 9.16% to $92.9 million in 2023, then skyrocketed by 93.57% to $179.9 million in 2024.